Lipid-based nanoparticles

Why use lipid-based nanoparticles?

Lipid-based nanoparticles have attracted significant interest in the last two decades and have achieved tremendous clinical success since the first clinical approval of Doxil in 1995. Many have since been approved for clinical use, demonstrating their unique advantages compared to other drug delivery systems.

As drug delivery systems, lipid-based nanoparticles offer many attractive benefits, such as great biocompatibility, ease of preparation, the feasibility of scale-up, nontoxicity and targeted delivery. With the capacity to encapsulate a variety of therapeutic agents — including small molecules, nucleic acids and antibodies — they can be used for a wide range of applications.

Our analytical development expertise

Our analytical team brings specialist expertise in the characterisation of lipid-based nanoparticles — covering not just particle size and zeta potential, but the full range of critical quality attributes that regulators expect and scientists need. We quantify lipids including PEGylated phospholipids and cationic lipids, their related impurities, and encapsulated payloads across small molecules, peptides, oligonucleotides, and mRNA. Orthogonal techniques for size distribution, morphology, surface charge, and in vitro release ensure thorough characterisation and sound regulatory documentation.